Belvedere Trading
CLDX icon

Belvedere Trading’s Celldex Therapeutics CLDX Stock Holding History

Belvedere Trading’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-9,191
Closed -$416K – 474
2021
Q3 		$416K Buy
+9,191
New +$431K 0.01% 131

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Belvedere Trading's CLDX Position: Q4 2021 in Review

Belvedere Trading sold out of Celldex Therapeutics (CLDX) in Q4 2021, closing a stake of 9,191 shares — an estimated $416K sold.

Belvedere Trading first reported a position in CLDX in Q3 2021 and held it in 1 quarter. The position peaked at $416K in Q3 2021. 180 funds tracked by Wall St. Rank hold CLDX as of Q4 2021.

  • Belvedere Trading reported no remaining Celldex Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Belvedere Trading sold 9,191 Celldex Therapeutics shares in Q4 2021, an estimated $416K.
  • Belvedere Trading first reported a position in Celldex Therapeutics in Q3 2021 and held it in 1 quarter.
  • Belvedere Trading's Celldex Therapeutics position peaked at $416K in Q3 2021.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2021.

Based on Belvedere Trading's 13F filing for Q4 2021, filed 25 Jan 2022.